Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.

Continuous, nonconventional sunitinib dosing viable in metastatic renal cell carcinoma

20 Dec 2019

Alternative dosing regimens of sunitinib are feasible and appear to be more effective than standard dosing for the treatment of patients with metastatic renal cell carcinoma, reports a new study.

The investigators enrolled metastatic renal cell carcinoma patients treated with sunitinib between 1 July 2007 and 1 July 2011. They performed a retrospective review of medical records and dispensing data to categorize sunitinib dosing as intermittent (4 weeks treatment followed by 2 weeks rest), continuous (continuous daily dosing) or nonconventional (2 weeks on/1 week off).

Overall survival associated with the different dosing regimens was the primary outcome. Secondary outcomes were progression-free survival and incidence of treatment cessation due to adverse effects.

Of the 180 patients included, 120 (67 percent) received intermittent dosing, 32 (18 percent) continuous dosing and 28 (16 percent) nonconventional dosing.

Overall survival was comparable between continuous and intermittent dosing regimens (median, 13 vs 9 months; hazard ratio [HR], 0.67, 95 percent confidence interval, 0.43–1.06; p=0.088) and significantly better with nonconventional vs intermittent dosing (median, 23 vs 9 months; HR, 0.55, 95 percent CI, 0.34–0.90; p=0.016).

Compared with intermittent dosing, both continuous (median, 9 vs 4 months; HR, 0.61, 95 percent CI, 0.40–0.94; p=0.025) and nonconventional dosing (median, 10 vs 4 months; HR, 0.61, 95 percent CI, 0.39–0.95; p=0.03) were associated with longer progression-free survival.

One in five patients (20 percent) stopped treatment with sunitinib due to adverse effects. This finding was similar to that of previous sunitinib trials.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.